Ser393
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser393  -  WT1 (human)

Site Information
KTCQRKFsRSDHLKT   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 451121

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 1 ) , mutation of modification site ( 1 ) , phosphopeptide mapping ( 1 )
Relevant cell line - cell type - tissue:
COS (fibroblast) ( 1 ) , CV1 (fibroblast) ( 1 )

Upstream Regulation
Putative in vivo kinases:
PKACA (human) ( 1 )
Kinases, in vitro:
PKACA (human) ( 1 )
Treatments:
colforsin ( 1 )

Downstream Regulation
Effects of modification on biological processes:
transcription, altered ( 1 )

References 

1

Sakamoto Y, Yoshida M, Semba K, Hunter T (1997) Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain. Oncogene 15, 2001-12
9366517   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.